Effectiveness and Safety of Upadacitinib in Adults Older Than 50 Years With Moderate‐To‐Severe Atopic Dermatitis: A Multicenter Study

Francisco Javier Melgosa Ramos has received honoraria and/or travel grants and/or has acted as an advisory board member for Novartis, Abbvie, Janssen Cilag, UCB, Lilly, LEO Pharma, L'Oreal, Sanofi, Almirall, and Amgen. Lorena Vila Cobreros, Marta Galarreta Pascual, Santiago Guillén Climent, María Matellanes Palacios, Juncal Roca Ginés, Javier Sabater Abad, Eduardo Bernia Petit, Andrés Casanova Esquembre, Andrea Estébanez Corrales, and Carlos Abril Pérez declare no conflicts of interest regarding this manuscript. Victor González Delgado has received honoraria and/or travel grants and/or has acted as an advisory board member for Abbvie, Janssen Cilag, Lilly, LEO Pharma, Pfizer, Sanofi, Almirall, and Amgen. The other authors have no conflicts of interest to declare. All data are available upon request from the authors.